You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
信立泰(002294.SZ):擬以自有資金及子公司股權增資生物醫療
格隆匯 12-11 21:26

格隆匯 12 月 11日丨信立泰(002294.SZ)公佈,根據公司發展規劃,公司擬以自有資金3.1億元、以持有的蘇州桓晨醫療科技有限公司(“蘇州桓晨”)100%的股權(蘇州桓晨2282.6088萬元註冊資本對應的股權)作價18904.0618萬元、以持有的雅倫生物科技(北京)有限公司(“雅倫生物”)63.37%的股權(雅倫生物402.0521萬元註冊資本對應的股權)作價13906.7465萬元,對全資子公司深圳市信立泰生物醫療工程有限公司(“生物醫療”)增資。

增資完成後,生物醫療的註冊資本將由11224.4898萬元增加至75035.2981萬元;併成為蘇州桓晨、雅倫生物的控股股東,持有蘇州桓晨100%股權、雅倫生物63.37%股權。

生物醫療主要從事高端醫療器械的生產及研發,是公司主營領域的擴展,未來新的業績增長點。此次公司以持有的全資子公司蘇州桓晨、控股子公司雅倫生物股權增資生物醫療,有利於優化資產結構,理順業務架構,完善公司在醫療器械領域的佈局;以自有資金增資生物醫療,主要用於為生物醫療、雅倫生物等公司的在研產品提供資金支持,推進其產品上市進程,以及對公司醫療器械業務進行進一步整合,打造單病種解決方案,形成械械協同,拓寬總體戰略佈局,符合公司發展戰略和長遠規劃。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account